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OBJECTIVE
To compare different blood pressure (BP) levels in their associationwith the risk of
renal outcomes in type 1 diabetes and to determine whether an intensive glyce-
mic control strategy modifies this association.
RESEARCH DESIGN AND METHODS
We included 1,441 participants with type 1 diabetes between the ages of 13 and
39 years who had previously been randomized to receive intensive versus con-
ventional glycemic control in the Diabetes Control and Complications Trial (DCCT).
The exposures of interest were time-updated systolic BP (SBP) and diastolic BP
(DBP) categories. Outcomes included macroalbuminuria (>300 mg/24 h) or stage III
chronic kidney disease (CKD) (sustained estimated glomerular filtration
rate <60 mL/min/1.73 m2).
RESULTS
During a median follow-up time of 24 years, there were 84 cases of stage III CKD
and 169 cases of macroalbuminuria. In adjusted models, SBP in the <120 mmHg
range was associated with a 0.59 times higher risk of macroalbuminuria (95% CI
0.37–0.95) and a 0.32 times higher risk of stage III CKD (95% CI 0.14–0.75) com-
pared with SBPs between 130 and 140 mmHg. DBP in the <70 mmHg range were
associated with a 0.73 times higher risk of macroalbuminuria (95% CI 0.44–1.18)
and a 0.47 times higher risk of stage III CKD (95% CI 0.21–1.05) compared with
DBPs between 80 and 90 mmHg. No interaction was noted between BP and prior
DCCT-assigned glycemic control strategy (all P > 0.05).
CONCLUSIONS
A lower BP (<120/70 mmHg) was associated with a substantially lower risk of
adverse renal outcomes, regardless of the prior assigned glycemic control strat-
egy. Interventional trials may be useful to help determine whether the currently
recommended BP target of 140/90 mmHg may be too high for optimal renal
protection in type 1 diabetes.
The Joint National Committee and American Diabetes Association guidelines cur-
rently recommend a blood pressure (BP) target of,140/90mmHg for all adults with
diabetes, regardless of type (1–3). However, evidence used to support this recom-
mendation is primarily based on data from trials of type 2 diabetes (4–6). The
relationship between BP and adverse outcomes in type 1 and type 2 diabetes
may differ, given that the type 1 diabetes population is typically much younger at
disease onset, hypertension is less frequently present at diagnosis (3), and the basis
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for the pathophysiology and disease
complications may differ between the
two populations.
Prior prospective cohort studies (7,8)
of patients with type 1 diabetes sug-
gested that lower BP levels (,110–
120/70–80 mmHg) at baseline entry
were associated with a lower risk of ad-
verse renal outcomes, including incident
microalbuminuria. In one trial of antihy-
pertensive treatment in type 1 diabetes
(9), assignment to a lower mean arterial
pressure (MAP) target of ,92 mmHg
(corresponding to ;125/75 mmHg) led
to a significant reduction in proteinuria
compared with a MAP target of 100–
107 mmHg (corresponding to ;130–
140/85–90 mmHg). Thus, it is possible
that lower BP (,120/80mmHg) reduces
the risk of important renal outcomes,
such as proteinuria, in patients with
type 1 diabetes and may provide a syn-
ergistic benefit with intensive glycemic
control on renal outcomes (10–12).
However, fewer studies have examined
the association between BP levels over
time and the risk of more advanced re-
nal outcomes, such as stage III chronic
kidney disease (CKD) or end-stage renal
disease (ESRD), during long-term follow-
up. One recent report (13) in a large co-
hort of patients with type 1diabeteswith
established diabetic nephropathy indi-
cated that survival has improved and
the loss of renal function has diminished
over time, along with better control of
modifiable risk factors such as BP. Given
the typical long duration before the onset
of more serious renal complications in
type 1 diabetes, the use of observational
data to help support or refute the poten-
tial use of future BP-lowering trials on the
risk of renal outcomes would be useful in
this population.
The primary objective of this study
was to determine whether there is an
association between lower BP levels
and the risk of more advanced diabetic
nephropathy, defined as macroalbumi-
nuria or stage III CKD, within a back-
ground of different glycemic control
strategies using data from the Diabetes
Control and Complications Trial (DCCT).
We hypothesized that exposure to
BPs ,120/80 mmHg would be associ-
ated with a lower risk of macroalbumi-
nuria and CKD and that there would be a
stepwise increase in the risk of adverse
renal outcomes with stepwise increases
in BP levels. We also hypothesized that
the association of BP and outcomes would
be weaker in participants formerly as-
signed to receive intensive glycemic con-
trol during the DCCT.
RESEARCH DESIGN AND METHODS
The DCCT randomized 1,441 partici-
pants between the ages of 13 and
39 years with type 1 diabetes to inten-
sive (hemoglobin A1c goal of ,6% or
42 mmol/mol) versus conventional gly-
cemic control between 1983 and 1993.
A primary prevention cohort (diabetes
for ,5 years, albumin excretion rate
,40 mg/24 h, and no retinopathy)
and a secondary prevention cohort (di-
abetes duration of 1–20 years, albumin
excretion rate #200 mg/24 h, and no
more than moderate nonproliferative
retinopathy) were included. Details of
the trial have been described previously
(14). Participants with a BP .140/90
mmHg or a history of treatment for hy-
pertension during the 2 years prior to
randomization were excluded.
At the conclusion of the DCCT, 96% of
participants (N = 1,375) enrolled in the
Epidemiology of Diabetes Interventions
and Complications (EDIC) observational
phase of the study, which is still ongoing
(15). All participants in the conventional
glycemic control arm were offered in-
struction in intensive glycemic control,
and participants in the intensive glyce-
mic control arm were encouraged to
continue intensive glycemic control. Af-
ter the trial, all participants returned to
their own providers for care. The current
study includes DCCT and EDIC follow-up
through 2012 (year 18 of the EDIC).
BP Measurements
During the DCCT and EDIC, BP was mea-
sured by trained observers in a stan-
dardized fashion after 5 min of rest
every 3 months during the DCCT and
annually during the EDIC (11). If BP
was $140/90 mmHg, participants were
asked to return in a month for repeat
measurement during the DCCT and
received a diagnosis of hypertension
only if BP remained above this threshold.
BPs ,140/90 mmHg were not treated
during the DCCT. Data on the use of
antihypertensive medications, includ-
ing the renin-angiotensin-aldosterone
system (RAAS) blockers, were collected
at all annual visits. The use of RAAS
blockers was discouraged during the
DCCT.
Predictors of Interest
Only BP measurements taken at the an-
nual visits in the DCCT and EDIC were in-
cluded for analysis. In our primary analysis,
time-updated systolic BP (SBP) was cate-
gorized as ,120 mmHg, 120 to ,130
mmHg, 130 to ,140 mmHg, and $140
mmHg. Time-updated diastolic BP (DBP)
was categorized as ,70 mmHg, 70 to
,80 mmHg, 80 to ,90 mmHg, and
$90 mmHg. For all predictors of interest,
a 1-year time lagwas used to examine the
association between BP and outcomes
(e.g., year 0 BP measurements were used
as predictors of year 1 outcomes). We
chose to categorizeBPs as our primarypre-
dictor to facilitate the comparison of re-
sults to current guideline-recommended
BP targets. We selected SBPs in the range
of 130 to ,140 mmHg and DBPs in the
range of 80 to ,90 mmHg that would
not warrant treatment according to cur-
rent hypertension guidelines as the ref-
erence group. In a secondary analysis,
time-updated SBP and DBP (with a
1-year lag) were also used as continuous
predictors of all outcomes of interest.
Outcomes of Interest
The primary outcomes of interest were
macroalbuminuria and stage III CKD.
Urine albumin levels were measured
yearly during the DCCT and every 2 years
during the EDIC using 4-h timed collec-
tions that were expressed as 24-h rates,
as previously described (10). As per prior
DCCT and EDIC studies, macroalbuminuria
was defined as the first visit where the
urine albumin concentration was .300
mg/day (10). Stage III CKD was defined
as a sustained estimated glomerular filtra-
tion rate (eGFR) of ,60 mL/min/1.73 m2
on two consecutive visits according to the
Chronic Kidney Disease Epidemiology Col-
laboration (CKD-EPI) equation (10,16). Se-
rum creatinine values were measured
yearly and were retrospectively recali-
brated to isotope dilution mass spectro-
photometry-traceable values if values
were obtained prior to 2007 (12).
Secondary outcomes of interest in-
cluded incident sustained microalbumi-
nuria, defined as two consecutive visits
when the urine albumin level was $30
mg/24 h (16); sustained eGFR of ,90
mL/min/1.73 m2; and the onset of
ESRD (receipt of dialysis or transplant).
Statistical Analysis
In primary analysis, time-updated Cox
models were used to examine the
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association between BP categories and
outcomes of interest in separate models
for SBP and DBP. The base model was
stratified on primary versus secondary
prevention cohorts (to accommodate
nonproportionality in risk) andwere con-
trolled only for the assigned glycemic
control strategy during the DCCT (model
1). We subsequently added fixed co-
variates measured at baseline entry,
including age, sex, race, education,
family history of hypertension, albu-
minuria, smoking status, and eGFR
(model 2). We then additionally ad-
justed for time-updated covariates
including BMI, smoking status, use of
antihypertensive medications (yes/no),
eGFR, albuminuria, hemoglobin A1c
level, and use of ACE inhibitors or
angiotensin receptor blockers (ARBs)
ascertained at the same time as the
time-updated BP measurements (model
3). Our primary analysis was based on
model 3, with a 1-year lag built into our
Cox models between BP and outcome
ascertainment. All time-dependent co-
variates were updated annually, and
missing values were carried forward
from the prior year. In additional analy-
ses, we also performed adjusted Cox
models with 4-year and 7-year lags built
into our models (the approximate mean
follow-up duration of the DCCT) between
BP and outcome ascertainment to ensure
that BP levels temporally precede the on-
set of kidney disease and are less likely to
be a consequence of kidney disease.
We subsequently tested for the pres-
ence of interaction between SBP and
DBP (as continuous predictors to maxi-
mize power) and assigned glycemic con-
trol strategy during DCCT to assess for
effect modification.
In a secondary analysis, we repeated
our models using 1-year lagged SBP and
DBP as continuous predictors in fully ad-
justedmodels (model 3) for all outcomes.
To assess for the presence of nonlinear-
ities in the association between BP and
outcomes of interest, quadratic BP terms
(SBP or DBP) were added to adjusted Cox
models and tested for statistical signifi-
cance. To determine whether SBP or DBP
was a more important predictor of ad-
verse renal outcomes, we included both
parameters as continuous predictors in
the same Cox model. We also evaluated
the association among baseline BP val-
ues as continuous predictors of our pri-
mary outcomes.
Finally, to attempt to isolate the asso-
ciation between treated BP levels and
renal outcomes of interest, we used
SBP and DBP as continuous predictors
in Cox models restricted to the duration
of follow-up when participants reported
active use of antihypertensive agents.
We also tested formally for the presence
of interaction between antihyperten-
sive therapy and SBP or DBP categories.
All data used were deidentified and
obtained from the National Institute of
Diabetes and Digestive and Kidney Dis-
eases data repository. The University of
California, San Francisco, Institutional
Review Board considers this study “ex-
empt” human subjects research. All
analyses were conducted using Stata 13.
RESULTS
The baseline characteristics of partici-
pants at the time of enrollment in the
DCCT are shown in Table 1. The mean
age of participants was 27 years, and
.96% were white. No participant had
macroalbuminuria or stage III CKD at
the time of entry into the DCCT. During
the trial, the mean hemoglobin A1c level
was 7.3% (56 mmol/mol) in the inten-
sive glycemic control arm and 9.1%
(76 mmol/mol) in the conventional gly-
cemic control arm and converged to 8%
during the EDIC phase of the study
(12,14). After a mean follow-up time of
6.5 years during the DCCT, intensive gly-
cemic control was found to delay the
onset of diabetic retinopathy, neuropa-
thy, and nephropathy (14).
Macroalbuminuria developed in a to-
tal of 169 participants (0.54 cases/100
person-years) and stage III CKD devel-
oped in 84 participants (0.26 cases/100
person-years) during a median follow-
up time of 24 years. Among those in
whom CKD developed, the mean quali-
fying eGFR at incident CKD was 47.4 6
11.6 mL/min/1.73 m2. In our primary
analysis, SBP ,120 mmHg, but not
DBP ,70 mmHg, was associated with a
statistically significant lower risk of mac-
roalbuminuria and stage III CKD com-
pared with reference BPs (Table 2). In
fully adjusted models, SBPs in the range
of 120 to ,130 mmHg and DBPs in the
range of 80 to ,90 mmHg also trended
toward a lower risk of macroalbuminuria,
but these associations did not achieve sta-
tistical significance. BPs $140/90 mmHg
Table 1—Baseline characteristics at time of enrollment in DCCT by SBP category
Baseline characteristics at DCCT enrollment
SBP ,120 mmHg
(N = 908)
SBP 120 to,130 mmHg
(N = 376)
SBP 130 to,140 mmHg
(N = 135)
SBP $140 mmHg
(N = 22)
Age, mean 6 SD (years) 26.2 6 7.3 27.6 6 6.8 28.1 6 6.2 29.4 6 5.7
Female sex, N (%) 516 (56.8) 137 (36.4) 25 (18.5) 2 (9.1)
White, N (%) 871 (95.9) 366 (97.3) 132 (97.8) 22 (100.0)
Education, mean 6 SD (years) 13.9 6 2.3 14.3 6 2.2 14.5 6 2.1 15.0 6 1.7
Family history of hypertension, N (%) 502 (55.3) 215 (57.2) 83 (61.5) 11 (50.0)
Duration of diabetes, median (IQR) (years) 3.9 (2.1–8.7) 4.3 (2.2–8.9) 4.7 (2.3–10.1) 9.7 (3.9–11.9)
Retinopathy at baseline, N (%) 428 (47.1) 191 (50.8) 78 (57.8) 18 (81.8)
BMI, mean 6 SD (kg/m2) 23.1 6 2.7 23.8 6 2.7 24.7 6 2.8 24.7 6 2.7
Hemoglobin A1c, mean 6 SD (%) 9.0 6 1.6 8.8 6 1.5 8.6 6 1.5 8.8 6 1.1
Serum creatinine, mean 6 SD (mg/dL) 0.78 6 0.15 0.82 6 0.14 0.88 6 0.15 0.90 6 0.11
eGFR by CKD-EPI equation, mean 6 SD
(mL/min/1.73 m2) 127.0 6 14.9 125.4 6 12.8 123.0 6 13.0 120.5 6 9.3
Microalbuminuria ($30 mg/day), N (%) 89 (9.8) 46 (12.2) 16 (11.9) 6 (27.3)
All percentages are provided by category of BP. IQR, interquartile range.
2220 BP and Renal Outcomes in Type 1 Diabetes Diabetes Care Volume 39, December 2016
were associated with a statistically signifi-
cant higher risk of macroalbuminuria and
stage III CKD compared with reference BPs
(Tables 2 and 3). Tests for interaction be-
tween SBP or DBP (as continuous predic-
tors) and glycemic control strategy did not
achieve statistical significance (all P .
0.05).
In sensitivity analysis, the association
between BP and outcomes using a 4-year
or 7-year lag between BP categories and
outcome ascertainment were attenuated
in some cases, although SBP,120 mmHg
andDBP,70mmHg remained statistically
significantly associated with a lower risk of
stage III CKD (Supplementary Table 1).
There was no statistically significant asso-
ciation between lower BP and macroalbu-
minuria in our sensitivity analysis when
incorporating a 7-year lag.
In continuous models, lower SBP and
DBP levels were also associated with a
lower risk of macroalbuminuria and
stage III CKD (Table 4). The test for non-
linearities in the association between BP
and primary outcomes of interest did
not achieve statistical significance (all
P . 0.10). When SBP and DBP were
both included in the same model, SBP,
but not DBP, was associated with our
primary outcomes (Table 4). There was
no statistically significant association
between baseline BP measurements at
DCCT entry and our primary outcomes
(Table 4).
In terms of secondary outcomes of
interest, incident microalbuminuria devel-
oped in 363 participants (1.38 cases/100
person-years), 472 participants (1.60
cases/100-person-years) had eGFR de-
cline to ,90 mL/min/1.73 m2, and
ESRD developed in 26 participants (0.08
cases/100 person-years) during long-
term follow-up. Every 10mmHg increase
in SBP was associated with a 1.25 times
higher risk of microalbuminuria (95% CI
1.15–1.37), a 1.13 times higher risk of
eGFR decline to ,90 mL/min/1.73 m2
(95% CI 1.05–1.21), and a 1.04 times
higher risk of ESRD (95% CI 0.77–1.41)
in adjusted Cox models. Every 10 mmHg
increase in DBP was associated with a
1.17 times higher risk of microalbuminuria
(95%CI 1.03–1.32), a 1.15 times higher risk
of eGFR decline to ,90 mL/min/1.73 m2
(95% CI 1.04–1.29), and a 0.80 times
higher risk of ESRD (95% CI 0.47–1.38) in
adjusted models.
Finally, in an exploratory analysis us-
ing our fully adjusted model, the risk of
macroalbuminuria during the follow-up
that was attributed to active antihyper-
tensive therapy (N = 910) was 1.56 times
higher (95% CI 1.29–1.88) with every
10 mmHg increase in SBP and 1.37 times
higher for every 10 mmHg increase in
Table 3—Risk of stage III CKD during long-term follow-up in DCCT and EDIC studies
Model 1
HR (95% CI) P value
Model 2
HR (95% CI) P value
Model 3
HR (95% CI) P value
SBP category
$140 mmHg 3.49 (1.95–6.27) ,0.001 3.45 (1.91–6.21) ,0.001 1.89 (1.00–3.57) 0.05
130 to ,140 mmHg Reference Reference Reference
120 to ,130 mmHg 0.75 (0.40–1.39) 0.36 0.75 (0.40–1.41) 0.38 1.46 (0.75–2.83) 0.27
,120 mmHg 0.15 (0.07–0.34) ,0.001 0.15 (0.07–0.34) ,0.001 0.32 (0.14–0.75) 0.009
DBP category
$90 mmHg 4.37 (2.40–7.95) ,0.001 4.33 (2.37–7.93) ,0.001 2.07 (1.03–4.17) 0.04
80 to ,90 mmHg Reference Reference Reference
70 to ,80 mmHg 0.72 (0.42–1.23) 0.23 0.69 (0.40–1.19) 0.18 1.11 (0.61–2.01) 0.73
,70 mmHg 0.33 (0.16–0.70) 0.004 0.30 (0.14–0.63) 0.002 0.47 (0.21–1.05) 0.07
Model 1, stratified on primary vs. secondary prevention cohort and adjusted for DCCT randomization arm (intensive glycemic control strategy), with
reference group being SBP 130 to ,140 mmHg or DBP 80 to ,90 mmHg; model 2, adjusted additionally for baseline factors including age, sex,
race, education, family history of hypertension, albuminuria, smoking status (ever smoked, yes/no), and baseline eGFR (by CKD-EPI equation);model
3, additionally adjusted for time-updated covariates including hemoglobin A1c, BMI, use of any antihypertensive medication, smoking status,
use of RAAS blockade (ACE inhibitor or ARB), albuminuria, and eGFR (all with 1-year lag). HR, hazard ratio.
Table 2—Risk of macroalbuminuria during long-term follow-up in DCCT and EDIC
Model 1
HR (95% CI) P value
Model 2
HR (95% CI) P value
Model 3
HR (95% CI) P value
SBP category
$140 mmHg 2.95 (1.84–4.74) ,0.001 3.12 (1.94–5.04) ,0.001 2.77 (1.68–4.57) ,0.001
130 to ,140 mmHg Reference Reference Reference
120 to ,130 mmHg 0.65 (0.42–1.02) 0.06 0.63 (0.40–0.99) 0.047 0.85 (0.53–1.36) 0.49
,120 mmHg 0.36 (0.23–0.56) ,0.001 0.37 (0.24–0.59) ,0.001 0.59 (0.37–0.95) 0.03
DBP category
$90 mmHg 2.16 (1.32–3.53) 0.002 2.00 (1.22–3.27) 0.006 1.79 (1.08–2.98) 0.03
80 to ,90 mmHg Reference Reference Reference
70 to ,80 mmHg 0.49 (0.34–0.70) ,0.001 0.51 (0.35–0.73) ,0.001 0.71 (0.48–1.04) 0.08
,70 mmHg 0.39 (0.25–0.61) ,0.001 0.45 (0.28–0.71) 0.001 0.73 (0.44–1.18) 0.20
Model 1, stratified on primary vs. secondary prevention cohort and adjusted for DCCT randomization arm (intensive glycemic control strategy), with
reference group being SBP 130 to ,140 mmHg or DBP 80 to ,90 mmHg; model 2, adjusted additionally for baseline factors, including age, sex,
race, education, family history of hypertension, albuminuria, smoking status (ever smoked, yes/no), and baseline eGFR (by CKD-EPI equation);
model 3, additionally adjusted for time-dependent covariates including hemoglobin A1c, BMI, use of any antihypertensive medication, smoking
status, use of RAAS blockade (ACE inhibitor or ARB), albuminuria, and eGFR (all with 1-year lag). HR, hazard ratio.
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DBP (95% CI 1.01–1.84). The risk of stage
III CKD among participants receiving an-
tihypertensive treatment (N = 988) was
1.27 times higher (95% CI 1.10–1.47) for
every 10mmHg increase in SBP and 1.32
times higher (95% CI 1.01–1.72) for ev-
ery 10 mmHg increase in DBP. Test re-
sults for the interaction between SBP
and DBP and antihypertensive medica-
tion use did not achieve statistical signif-
icance for any primary outcome of
interest (all P . 0.10).
CONCLUSIONS
The primary objective of this study was
to determine the stepwise association
between lower BPs (to levels ,120/80
mmHg) and the risk of adverse renal
outcomes. We also aimed to determine
whether exposure to intensive glycemic
control would modify any benefit asso-
ciated with lower BPs. We hypothesized
and found that SBPs ,120 mmHg were
associated with a statistically significant
lower risk of our primary outcomes of
macroalbuminuria and incident stage
III CKD compared with reference BPs in
the range of 130 to,140 mmHg range.
DBPs,70 mmHg trended toward lower
risk of macroalbuminuria and stage III
CKD, although this finding did not
achieve statistical significance. Contrary
to our hypothesis, these results were in-
dependent of assigned glycemic control
strategy during DCCT or achieved hemo-
globin A1c levels during the DCCT and
EDIC. We also found that lower BPs
were associated with a lower risk of mi-
croalbuminuria and milder declines in
renal function.
Recently, both the Joint National
Committee and the American Diabetes
Association revised recommendations
for BP targets in patients with type 1
and type 2 diabetes from ,130/80
to ,140/90 mmHg (1,2,17). The ratio-
nale for this change stemmed primarily
from the lack of solid trial-based evi-
dence to support the benefit of a lower
BP target in patients with diabetes (1,2).
For example, in the Action to Control Car-
diovascular Risk in Diabetes (ACCORD)
trial, intensive BP lowering (to an SBP
goal of 120 vs. 140 mmHg) did not re-
duce the risk of a composite outcome of
cardiovascular events and death among
patients with type 2 diabetes (6). How-
ever, few trials have been conducted to
test the benefit of alternate BP targets
on the risk of adverse renal outcomes in
the type 1 diabetes population. It is pos-
sible that patients with type 1 diabetes
could have a different association be-
tween BP level and renal outcomes com-
paredwith patients with type 2 diabetes,
given the younger age of disease onset,
the earlier diagnosis, and the lower prev-
alence of comorbidities, such as obesity
at the time of type 1 diabetes onset (18).
In the absence of randomized controlled
trials on outcomes, such as incident CKD
in type 1 diabetes, the observational
data in DCCT and EDIC could serve to
provide support for the conduct of inter-
ventional trials to further test the hy-
pothesis that tight BP control would
delay the onset and progression of clin-
ical renal disease in this population.
In randomized controlled trials of
normotensive persons (defined as DBP
of,90 mmHg) with type 1 diabetes trea-
tedwith RAAS blockade, persons random-
ized to receive RAAS blockade (who
achieved a 3–7mmHg lower BP compared
with the placebo arm) had a lower risk of
worsening overt proteinuria, thus sug-
gesting the benefit of lower BP levels on
renal outcomes (19,20). Another small tri-
al demonstrated a benefit to lowering
MAP to ,92 mmHg (corresponding to
;125/75 mmHg) on the reduction of
proteinuria (mean 535 mg/24 h vs.
1,723 mg/24 h in the MAP target of
100–107mmHg) but not on renal function
decline during 2 years of follow-up (9).
Observational studies (21) have shown
that persistent microalbuminuria is more
likely to develop in normotensive normo-
albuminuric patients with higher baseline
BP valueswhohave type1diabetes during
follow-up. Elevations in SBP during sleep
have been found to precede the onset of
microalbuminuria in otherwise normoten-
sive normoalbuminuric adolescents and
youngadultswith type1diabetes (21–23).
Our study expands upon the results
from prior studies by providing data
from a larger and well-characterized
population on the risk of more ad-
vanced renal end points, including stage
III CKD, during nearly 30 years of follow-
up. Our study is also unique in the use
of time-updated BPs and hemoglobin
A1c measures, which may reduce the
misclassification bias of BP status and gly-
cemic control during long-term follow-up.
In fact, we found that baseline SBP and
DBP values at DCCT entry were poorly
predictive of the long-term risk of adverse
renal outcomes in our study (24–27).
Table 4—Comparison of risk of renal outcomes of interest using SBP and DBP as linear predictors
Model for SBP
HR (per 10 mmHg
SBP increase)
(95% CI) P value Model for DBP
HR (per 10 mmHg
DBP increase)
(95% CI) P value
Macroalbuminuria
Baseline SBP1 1.00 (0.86–1.17) 0.98 Baseline DBP1 1.04 (0.86–1.26) 0.69
Time-updated SBP 1.44 (1.28–1.62) ,0.001 Time-updated DBP 1.32 (1.10–1.59) 0.003
Time-updated SBP and
DBP in same model
1.47 (1.28–1.69) ,0.001 Time-updated SBP and
DBP in same model
0.95 (0.77–1.18) 0.64
Stage III CKD
Baseline SBP1 0.96 (0.78–1.18) 0.68 Baseline DBP1 1.23 (0.94–1.61) 0.13
Time-updated SBP 1.34 (1.16–1.54) ,0.001 Time-updated DBP 1.41 (1.09–1.82) 0.009
Time-updated SBP and
DBP in same model
1.32 (1.11–1.57) 0.002 Time-updated SBP and
DBP in same model
1.04 (0.76–1.43) 0.78
All models were adjusted for age, race, sex, education, family history of hypertension, trial arm, and time-dependent covariates, including BMI, use
of any antihypertensive medication, albuminuria, eGFR, smoking status, hemoglobin A1c, and use of ACE inhibitors or ARB (all with 1-year lag),
unless otherwise specified. HR, hazard ratio. 1Models were adjusted for baseline age, sex, race, education level, family history of hypertension,
smoking status, albuminuria, eGFR, trial arm, and BMI.
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Multiple follow-up studies using the
DCCT/EDIC cohort (10–12,24) have
demonstrated the importance of glyce-
mic control in preventing long-term
renal sequelae, including the onset of
hypertension,microalbuminuria,macro-
albuminuria, and CKD. It is plausible,
however, that intensive glycemic con-
trol and BP control may provide syner-
gistic and additive renal protection in
patients with type 1 diabetes. The re-
sults of animal studies (25,26) have sug-
gested an additive interaction between
diabetes and hypertension, in which
both contribute to enhanced vascular
permeability to albumin and monocyte
adhesiveness to the endothelium (a first
step in atherogenesis). Our study sug-
gests that even in participants who had
been previously exposed to intensive gly-
cemic control, lower BPwas still associated
with a lower risk of adverse renal out-
comes. We believe this finding to be im-
portant, as the traditional focus in type 1
diabetes research and clinical practice has
been on the effects of intensive glycemic
control (10,11).Wewould suggest that our
finding between lower BP and renal out-
comes supports the need for future inter-
ventional studies, because BP treatment
may be less costly and more achievable
than other treatment options.
The large effect size of lower BPs ob-
served in our study may be due to the
long duration of follow-up, and the
accurate assessment of both the predic-
tor of interest and other confounding
factors that are likely to change over
time, such as antihypertensive use, he-
moglobin A1c level, and BMI, all of which
were prospectively collected per the re-
search protocol. When restricting our
analyses to the duration of follow-up
when patients actively received antihy-
pertensive drug therapy, we observed
similar effect sizes for renal protection
in those patients treated to lower BP
levels, suggesting a potential benefit to
antihypertensive therapy. We note that,
in our sensitivity analysis with a 7-year
imposed lag, the association between
lower BP and lower risk of adverse out-
comes only achieved statistical signifi-
cance for incident CKD, and not for
macroalbuminuria. Whether this attenu-
ation is due to diminished power (given
the obligatory exclusion of .25% events
from our analysis when we enforce a
7-year lag between BP and outcome as-
certainment), reverse causation (in that
worsened renal injury and/or function
can also lead to worsened BP) or the
tendency for BP levels to have shorter-
term associations with albuminuria
(due to hemodynamic responses to BP
changes or albuminuria-lowering ef-
fects of BP medications) are unclear.
Finally, our fully adjusted models may
be overly conservative in their adjust-
ment for time-updated albuminuria
and eGFR, given that our primary out-
comes of interest are macroalbuminuria
and stage III CKD.
Although the results of this study are
compatible with the hypothesis that lower
BP targets may reduce complications in
the younger type 1 diabetes population,
other explanations are also possible. For
example, it is known that there is a strong
familial component to diabetic nephrop-
athy risk in type 1 diabetes (27,28) and
that a family history of hypertension is a
significant predictor of diabetic ne-
phropathy risk (29–31). It is possible
that the propensity to hypertension is
associated with a genetic predisposi-
tion to diabetic nephropathy through
pathways that are, at least in part, in-
dependent of systemic BP (32).
The strengths of our study include the
well-characterized cohort, the long du-
ration and completeness of follow-up,
the detailed collection of covariates
that may potentially confound the asso-
ciation between BP and renal outcomes,
and the use of models that account for
changes in time-varying covariates.
We also recognize a number of limita-
tions. Because these data are observa-
tional, they cannot prove causation. It
remainspossible that subtle kidneydisease
may lead to early elevations in BP, and we
cannot rule out the potential for reverse
causation in our findings. However, we
note similar trends in our data even
when imposing a 7-year lag between BP
and CKD ascertainment. Other limitations
include the use of a study cohort that is
predominantly white, which may limit the
ability to apply our results to other races.
The urinary measurements may also be
limited in their ability to capture potential
diurnal variations in albumin excretion.
In conclusion, there is an association
between BP levels that are significantly
below the current treatment guidelines
and the risk of adverse renal outcomes in
patientswith type 1diabetes, independent
of glycemic control. We believe that
these data provide a rationale for future
interventional trials designed to test the
hypothesis thatmore aggressive lowering
of BP could reduce the renal morbidities
associated with type 1 diabetes.
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